CK19与Bcl-2联合检测在甲状腺乳头状癌诊断中的意义

CK19 were associated with the Bcl - 2 test in the diagnosis of thyroid papillary carcinoma

目的探讨细胞角蛋白CK19、凋亡抑制基因Bcl-2在甲状腺乳头状癌中的表达及意义。方法收集2010—2014寿光市人民医院病理科临床资料完整的存档蜡块105例。应用免疫组织化学SP法研究甲状腺乳头状癌、甲状腺肿伴乳头状增生、瘤旁正常组织中CK19、Bcl-2的表达。研究对象包括甲状腺乳头状癌45例、甲状腺肿伴乳头状增生40例、瘤旁正常组织20例。结果甲状腺乳头状癌、甲状腺肿伴乳头状增生、瘤旁正常组织中CK19的阳性率分别为100．0％、25．0％和10．0％，Bcl-2的阳性率分别为73．3％、27．5％和5．0％。结论甲状腺乳头状癌中CK19、Bcl-2的表达明显高于甲状腺肿伴乳头状增生和瘤旁正常甲状腺组织（P〈O．05），且CK19的阳性表达与Bcl-2的阳性表达之间呈正相关关系。CK19在甲状腺乳头状癌的发生、发展中有促进细胞增殖的作用；与Bcl-2的联合检测在甲状腺乳头状癌的诊断中有重要的临床意义。

OBJECTIVE To study the role of cytokeratin 19 and Bcl-2 in different thyroid tissues. METHODS The expression of CK19 and Bcl-2 in 45 cases of papillary thyroid carcinomas and 40 cases of thyroid nodular goiter with papil lary hyperplasia and normal tissues around adenoma were detected by immunohistochemistry. RESULTS Among 45 cases of thyroid papillary carcinomas,45 cases were positive for CK19 and 33 cases were positive for Bcl-2. Among 40 cases of thyroid nodular goiter with papillary hyperplasia, 10 cases were positive for CK19 and 11 cases were positive for Bcl-2. CONCLUSION CK19 and Bcl-2 are useful markers for the differential diagnosis between papillary thyroid carcinomas and benign thyroid papillary hyperplasia.